ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7290-7300

  Charafe Jauffret, Emmanuelle ^a,b,c   Ginestier, Christophe ^a   Bertucci, François ^a,b,c   Cabaud, Olivier ^a   Wicinski, Julien ^a   Finetti, Pascal ^a   Josselin, Emmanuelle ^a   Adelaide, José ^a   Nguyen, Tien Tuan ^a   Monville, Florence ^a   Jacquemier, Jocelyne ^b   Thomassin Piana, Jeanne ^b   Pinna, Guillaume ^d   Jalaguier, Aurélie ^b   Lambaudie, Eric ^b   Houvenaeghel, Gilles ^b,c   Xerri, Luc ^b,c   Harel Bellan, Annick ^d   Chaffanet, Max ^a   Viens, Patrice ^a,b,c   Birnbaum, Daniel ^a   more..

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; PROTEIN ALDH1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL POPULATION; CELL RENEWAL; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; ISOENZYMES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; PROSPECTIVE STUDIES; RETINAL DEHYDROGENASE; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84891278007     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4704     Document Type: Article

References (47)

1. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 2009;138: 822-9.
2. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: Current opinion and future challenges. Pathobiology 2008;75:75-84.
3. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26:2813-20.
4. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: The 4 R's of radiobiology revisited. Stem Cells 2010;28: 639-48.
5. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44 breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
7. Visvader JE, Lindeman GJ. Stem cells and cancer - the promise and puzzles. Mol Oncol 2010;4:369-72.
8. Ishizawa K, Rasheed ZA, Karisch R,Wang Q, Kowalski J, Susky E, et al. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010;7:279-82.
9. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: A new concept in cancer therapeutics. BioDrugs 2007;21:299-310.
10. Korkaya H, Wicha MS. Cancer stem cells: Nature versus nurture. Nat Cell Biol 2010;12:419-21.
11. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010;28:4006-12.
12. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011;469:356-61.
13. Gibbs KD Jr, Jager A, Crespo O, Goltsev Y, Trejo A, Richard CE, et al. Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9- Meis1-driven AML. Cell Stem Cell 2012;10:210-7.
14. Visvader JE, Lindeman GJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012;10:717-28.
15. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488:522-6.
16. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012;488:527-30.
17. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012;338:1080-4.
18. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
19. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5.
21. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
22. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
23. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010;18:510-23.
24. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van GP, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011;17:1086-93.
25. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, et al. How different are luminal A and basal breast cancers Int J Cancer 2009;124:1338-48.
26. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006;25:2273-84.
27. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
28. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: Genetic insights into cell-cycle regulation. Nat Rev Genet 2008;9: 115-28.
29. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": Transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600.
30. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de CP, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13: 3989-98.
31. Valent P, Bonnet D, De MR, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: The devil is in the details. Nat Rev Cancer 2012;12:767-75.
32. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007;317:337.
33. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007;356:217-26.
34. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73.
35. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73.
36. Muhale FA, Wetmore BA, Thomas RS, McLeod HL. Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics 2011;12:341-50.
37. Sankar U, Means AR. Gfer is a critical regulator of HSC proliferation. Cell Cycle 2011;10:2263-8.
38. Teng EC, Todd LR, Ribar TJ, Lento W, Dimascio L, Means AR, et al. Gfer inhibits Jab1-mediated degradation of p27kip1 to restrict proliferation of hematopoietic stem cells. Mol Biol Cell 2011;22:1312-20.
39. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
40. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
41. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J Natl Cancer Inst 2006;98:1755-7.
42. Flis K, Irvine D, Copland M, Bhatia R, Skorski T. Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leuk Lymphoma 2012;53:2474-8.
43. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012;119:4253-63.
44. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 2012; 52:735-46.
45. Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012;30:1327-37.
46. Siolas D, Hannon GJ. Patient derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res 2013;73:5315-9.
47. Zhang X, Claerhout S, Prat A, Dobrolecki L, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenografts. Cancer Res 2013;73:4885-97.